Johanna Chiffelle

Oct 11, 2024 | nature.com | Florian Huber |Marion Arnaud |Fabrizio Benedetti |Jonathan Thevenet |Johanna Chiffelle |Markus K Muller | +7 more

AbstractThe accurate identification and prioritization of antigenic peptides is crucial for the development of personalized cancer immunotherapies. Publicly available pipelines to predict clinical neoantigens do not allow direct integration of mass spectrometry immunopeptidomics data, which can uncover antigenic peptides derived from various canonical and noncanonical sources.

Oct 11, 2024 | nature.com | Florian Huber |Marion Arnaud |Fabrizio Benedetti |Jonathan Thevenet |Johanna Chiffelle |Markus K Muller | +7 more

AbstractThe accurate identification and prioritization of antigenic peptides is crucial for the development of personalized cancer immunotherapies. Publicly available pipelines to predict clinical neoantigens do not allow direct integration of mass spectrometry immunopeptidomics data, which can uncover antigenic peptides derived from various canonical and noncanonical sources.

Jun 25, 2024 | nature.com | Remy Petremand |Johanna Chiffelle |Marion Arnaud |David Barras |Maria Lozano-Rabella |Raphael Genolet | +6 more

Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-024-02232-0, published online 7 May 2024In the version of the article initially published, there were errors in Extended Data Fig. 5e. One patient was erroneously omitted due to an inaccurate y-axis scale, and in the key “n = 17” has been corrected to “n = 12”. These corrections have been made to the HTML and PDF versions of the article.

Jun 25, 2024 | nature.com | Remy Petremand |Johanna Chiffelle |Marion Arnaud |David Barras |Maria Lozano-Rabella |Raphael Genolet | +6 more

Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-024-02232-0, published online 7 May 2024In the version of the article initially published, there were errors in Extended Data Fig. 5e. One patient was erroneously omitted due to an inaccurate y-axis scale, and in the key “n = 17” has been corrected to “n = 12”. These corrections have been made to the HTML and PDF versions of the article.

Jun 11, 2024 | rupress.org | Lausanne Branch |Johanna Chiffelle |Alexandre Harari

In cancer research, antigens have long been recognized as pivotal triggers of immune responses and potential therapeutic targets. Antigens are commonly categorized into tumor-associated antigens (TAAs) or canonical neoantigens (Peri et al., 2023). TAAs are self-antigens, showing varied expression patterns within tumors.